Načítá se...
Profile of infliximab in the treatment of pediatric Crohn’s disease
In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn’s disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the grow...
Uloženo v:
| Vydáno v: | Pediatric Health Med Ther |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5683274/ https://ncbi.nlm.nih.gov/pubmed/29388577 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PHMT.S64943 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|